Your session is about to expire
← Back to Search
Immunotherapy + Radiation for Head and Neck Cancer
Study Summary
This trial is testing whether adding immunotherapy to radiation therapy can help people with head and neck cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is a type that started in my head or neck and has spread, with no cure from surgery or radiation.I have brain metastases that are either untreated, causing symptoms, or need treatment for symptoms.I need surgery to stabilize a bone before it can be treated with radiation.I have had allergic reactions or severe side effects to pembrolizumab or similar drugs.I am fully active or can carry out light work.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.I am HIV-positive and on combination antiretroviral therapy.I have had lung inflammation treated with steroids, or I currently have lung disease.I have an autoimmune disease treated with immune-modifying drugs in the last 2 years.I have not received a live vaccine in the last 30 days.My cancer progressed or didn't improve after treatment with a PD-1 inhibitor.I have at least 3 tumors outside the brain that can be measured and haven't been treated with radiation.I agree to have a research biopsy if my tumor can be reached.I haven't had chemotherapy, immunotherapy, or experimental drugs for at least 2 weeks.It has been at least 2 weeks since my last radiation therapy.I am not receiving any other cancer treatments while in this study.I am 18 or older and can medically handle the treatment.I am of childbearing age and have a negative pregnancy test.I agree to use birth control during and for 4 months after the study.My organ and bone marrow functions are normal based on lab tests.My cancer is pressing on my spinal cord or might soon.
- Group 1: High Dose + Low Dose Radiation + Pembrolizumab
- Group 2: High Dose Radiation + Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has research been done on the effects of Pembrolizumab in other contexts?
"Currently, there are 961 examinations of Pembrolizumab being conducted with 122 studies in their culminating phase. Most tests for this treatment occur in Houston, TX; however, clinical trials can be found at 35727 different sites worldwide."
Are there still opportunities to enroll in this research endeavor?
"Indeed, clinicaltrials.gov reveals that this trial is now searching for participants. It was initially revealed on June 30th 2017 and edited as recently as November 28th 2022. 26 individuals are being recruited from 1 medical site."
Are there any afflictions that Pembrolizumab has been demonstrated to alleviate?
"Pembrolizumab is commonly used to combat malignant neoplasms, and can also be a potential treatment for those with unresectable melanoma, microsatellite instability high, or are dealing with disease progression after chemotherapy."
What is the upper limit of subjects taking part in this experiment?
"Affirmative. Data hosted on clinicaltrials.gov suggests that this medical trial is in the recruitment phase, which was first initiated June 30th 2017 and last updated November 28th 2022. 26 patients are anticipated to be enrolled at a single research centre."
Does Pembrolizumab pose any risks to the individuals taking it?
"The security of pembrolizumab has been evaluated by the Power team and given a score of 2 as this is still in phase two. Thus far, safety data exists but not efficacy information."
Share this study with friends
Copy Link
Messenger